Event JSON
{
"id": "cfc4a65e10d5ffcad7aab992fcaca3d2b3d3757dabd49387bcf8b0e398b52d10",
"pubkey": "de1abdd3127788ab39fb6f558233067d7cf07e8165598738c9a46a9cff3979a0",
"created_at": 1744798407,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/analysis-pharma-companies-expected-absorb-100345370.html"
],
[
"subject",
"Analysis-Pharma companies expected to absorb any tariff hit in short term"
],
[
"published_at",
"1744797825"
],
[
"image",
"https://media.zenfs.com/en/reuters-finance.com/db3453d8c7ca463c4dcab71f62447088"
],
[
"p",
"de1abdd3127788ab39fb6f558233067d7cf07e8165598738c9a46a9cff3979a0",
"wss://articles.layer3.news"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://media.zenfs.com/en/reuters-finance.com/db3453d8c7ca463c4dcab71f62447088"
],
[
"t",
"Deena Beasley"
],
[
"t",
"Melissa Barber"
],
[
"t",
"Robin Feldman"
],
[
"t",
"Bill Coyle"
],
[
"t",
"Dave Ricks"
],
[
"t",
"William Padula"
],
[
"t",
"US"
],
[
"t",
"Yale University"
],
[
"t",
"India"
],
[
"t",
"China"
],
[
"t",
"European Union"
],
[
"t",
"Ireland"
],
[
"t",
"United States"
],
[
"t",
"health"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"The US tariffs on pharmaceuticals could lead to higher prices for brand-name medicines, but in the short term, the costs are likely to be absorbed by drugmakers rather than patients. The tariffs are part of a national security investigation into pharmaceuticals to boost domestic manufacturing. The industry has been lobbying for phased-in tariffs, and some experts believe that the real risk is to lower-margin, generic drugs."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqvap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aesst3mr8r\nANALYSIS-PHARMA COMPANIES EXPECTED TO ABSORB ANY TARIFF HIT IN SHORT TERM\n\nhttps://media.zenfs.com/en/reuters-finance.com/db3453d8c7ca463c4dcab71f62447088\n--\n✍️ The US tariffs on pharmaceuticals may lead to higher prices for brand-name medicines, but in the short term, the costs are likely to be absorbed by drugmakers rather than patients.\n--\n👉 US tariffs on pharmaceuticals may lead to higher prices for brand-name medicines\n👉 In the short term, the costs are likely to be absorbed by drugmakers rather than patients\n👉 The tariffs are part of a national security investigation into pharmaceuticals to boost domestic manufacturing\n👉 The industry has been lobbying for phased-in tariffs\n👉 Lower-margin, generic drugs are at risk of being affected by the tariffs\n\n--\n#DeenaBeasley #MelissaBarber #RobinFeldman #BillCoyle #DaveRicks #WilliamPadula #US #YaleUniversity #India #China #EuropeanUnion #Ireland #UnitedStates #health\n--\nnostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqt42aeln85y78nkeujawq2t8d0ms3nhwwgqznpvz7080defxcke3qj3nlpv \n ",
"sig": "b036f6b57a88c81ef11c3c9106d4227708aceb18c635de5ec7281d8304518be974b552c4edc3ae8f126da7621374f548769dffffd645719f8c00de232da5409a"
}
